Breast carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A carcinoma that arises from epithelial cells of the breast
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Breast carcinoma
- Therapeutic area
- Oncology
- breast carcinoma
- Advanced Breast Carcinoma
- Breast Cancer Nos Metastatic Recurrent
- Cancer Breast
- Cancer of the Breast
- carcinoma of breast
- carcinoma of the breast
- Locally Advanced Breast Carcinoma
- Locally Advanced Unresectable Breast Carcinoma
- mammary carcinoma
- Mammary Carcinoma, Human
- Metastatic Breast Carcinoma
- Newly Diagnosed Carcinoma of Breast
- Recurrent Breast Carcinoma
- Refractory Breast Carcinoma
- Stage I Breast Carcinoma
- Stage II Breast Carcinoma
- Stage III Breast Carcinoma
- Unresectable Breast Carcinoma
- breast cancer
- breast cancer, NOS
- cancer of breast
- cancer, breast
- All therapeutic areas
- Oncology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0004989
- Parent condition
- MONDO:0004993
Related records
Broader conditions (15)
- Breast cancer
- Breast disorder
- Breast neoplasm
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
- Thoracic cancer
Narrower conditions (83)
- Acantholytic variant squamous cell breast carcinoma
- Acinic cell breast carcinoma
- Adenoid cystic breast carcinoma
- Adenosquamous breast carcinoma
- Atypical lobular breast hyperplasia
- Basal-like breast carcinoma
- Bilateral breast carcinoma
- Breast adenocarcinoma
- Breast apocrine carcinoma
- Breast apocrine carcinoma in situ
- Breast carcinoma by gene expression profile
- Breast carcinoma in situ
- Breast columnar cell mucinous carcinoma
- Breast cystic hypersecretory carcinoma
- Breast ductal adenocarcinoma
- Breast large cell neuroendocrine carcinoma
- Breast lobular carcinoma
- Breast malignant eccrine spiradenoma
- Breast mucinous carcinoma
- Breast mucinous cystadenocarcinoma
Trials (305)
- 3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
- 3D Ultrasound Microvessel Imaging for Breast Masses
- 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy
- 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
- A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- A Correlational Study: Breast Cancer-related Chest Wall Lymphedema, Quality of Life, and Shoulder Function
- A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation
- A New Tool to Promote Patient's Engagement in Their Healthcare Process
- A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer
- A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
- A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
- A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
- A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
- A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
- A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
- A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
- A Safety Study of SGN-CD47M in Patients With Solid Tumors
- A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
Approved drugs (35)
- Abemaciclib
- Alpelisib
- Anastrozole
- Atezolizumab
- Bevacizumab
- Capecitabine
- Cyclophosphamide
- Denosumab
- Docetaxel
- Doxorubicin hydrochloride
- Epirubicin hydrochloride
- Eribulin mesylate
- Estradiol
- Everolimus
- Exemestane
- Fulvestrant
- Gemcitabine hydrochloride
- Goserelin acetate
- Ixabepilone
- Lapatinib ditosylate
Drugs in development (136)
- 2X-121 Phase 1
- Abiraterone acetate Phase 1
- AEG-35156 Phase 1
- Alisertib Phase 2
- Aspirin Phase 2
- AZD-8186 Phase 1
- Bicalutamide Phase 3
- Binimetinib Phase 2
- Bintrafusp alfa Phase 2
- Bortezomib Phase 2
- Bosutinib Phase 2
- Busulfan Phase 3
- Cabozantinib S-malate Phase 1
- Caffeine Phase 2
- Carboplatin Phase 3
- Carmustine Phase 3
- CDX-1140 Phase 1
- Cediranib Phase 2
- Celecoxib Phase 3
- Ceralasertib Phase 2